Barclays PLC Has $1.91 Million Position in Orthofix Medical Inc. (NASDAQ:OFIX)

Barclays PLC boosted its holdings in shares of Orthofix Medical Inc. (NASDAQ:OFIX) by 38.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 122,472 shares of the medical device company’s stock after buying an additional 34,210 shares during the period. Barclays PLC owned approximately 0.32% of Orthofix Medical worth $1,912,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in OFIX. nVerses Capital LLC bought a new stake in shares of Orthofix Medical during the second quarter worth about $27,000. Quest Partners LLC bought a new stake in Orthofix Medical during the 2nd quarter worth approximately $64,000. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Orthofix Medical by 25.5% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,435 shares of the medical device company’s stock worth $125,000 after purchasing an additional 1,919 shares during the last quarter. Arizona State Retirement System bought a new position in shares of Orthofix Medical in the second quarter valued at approximately $139,000. Finally, XTX Topco Ltd bought a new position in shares of Orthofix Medical in the second quarter valued at approximately $175,000. 89.76% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on OFIX. Roth Mkm reiterated a “buy” rating and set a $22.00 price target (up previously from $20.00) on shares of Orthofix Medical in a report on Friday, November 8th. Stifel Nicolaus upgraded shares of Orthofix Medical from a “hold” rating to a “buy” rating and upped their target price for the stock from $18.00 to $24.00 in a research note on Friday, November 8th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $23.00.

Orthofix Medical Stock Performance

OFIX stock opened at $17.83 on Friday. The company has a quick ratio of 1.11, a current ratio of 2.39 and a debt-to-equity ratio of 0.25. The firm has a market cap of $681.36 million, a PE ratio of -5.70 and a beta of 1.09. The business has a 50 day moving average of $17.92 and a 200-day moving average of $16.29. Orthofix Medical Inc. has a 12-month low of $12.08 and a 12-month high of $20.73.

Orthofix Medical Company Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.